OBI Pharma, Inc.

4174

TW0004174008

Biotechnology & Medical Research

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
61.5 ^TWD	-0.81%		+4.24%	-11.38%

Mar. 26	OBI Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 11	Obi Pharma, Inc. Announces the Termination of Obi-3424-001 Trial While Continuing the Collaboration Of obi-3424 with Partners	CI

OBI Pharma, Inc. Announces Appointment of Yun Yen as Natural-Person Director

June 27, 2023 at 02:35 am EDT

OBI Pharma, Inc. announced appointment of Yun Yen as Natural-person director with effect from June 27, 2023. Resume of the new position holder: Yun Yen/Chairman of the Board, OBI Pharma Inc.

Latest news about OBI Pharma, Inc.

OBI Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
Obi Pharma, Inc. Announces the Termination of Obi-3424-001 Trial While Continuing the Collaboration Of obi-3424 with Partners	Mar. 11	CI
OBI Pharma, Inc. Announces Adagloxad Simolenin (OBI-822) Receives Positive 1st Interim Analysis Recommendation, Recommending the Continues of the Phase III TNBC Trial	Jan. 31	CI
OBI Pharma, Inc. Announces OBI-992 TROP2 ADC Has Been Granted by US FDA to Proceed to Phase I/II Human Clinical Trial	Jan. 03	CI
OBI Pharma, Inc. Announces Resignation of Yun Yen as Chairperson and Director, Effective December 29, 2023	Dec. 20	CI
Obi Pharma, Inc. Files the Application of Phase I/II Human Clinical Trial for OBI-992 TROP2 ADC to US FDA	Dec. 01	CI
OBI Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
OBI Pharma, Inc. Announces Head Office Address Change	Nov. 06	CI
OBI Pharma, Inc. Announces Internal Audit Officer Changes	Nov. 06	CI
OBI Pharma, Inc. Announces CFO Changes	Nov. 06	CI
OBI Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
OBI Pharma, Inc. Announces Executive Changes	23-08-07	CI
OBI Pharma, Inc. Announces Appointment of Yun Yen as the Chairman	23-06-27	CI
OBI Pharma, Inc. Announces Appointment of Yun Yen as Natural-Person Director	23-06-27	CI
OBI Pharma, Inc. Announces COVID-19 Vaccine, BCVax, Has Been Granted by TFDA to Proceed to Phase I Clinical Trial	23-06-02	CI
OBI Pharma Appoints Heidi Wang as Chief Executive Officer	23-06-02	CI
OBI Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
OBI Pharma, Inc. Files the Application of Phase I Human Clinical Trial for COVID-19 Vaccine, BCVax, to TfDA	23-03-31	CI
OBI Pharma, Inc.(TPEX:4174) dropped from FTSE All-World Index	23-03-20	CI
OBI Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-15	CI
OBI Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-15	CI
Obi Pharma, Inc. Files Application for Phase II Human Clinical Trial of First-In-Class Novel Prodrug, Obi-3424, to TFDA	23-02-02	CI
OBI Pharma, Inc. Announces Demise of Chairman of the Board, Michael Chang	22-12-29	CI
United States Patent and Trademark Office Grants Patent for OBI-866 Immunogenic/Therapeutic Glycan Compositions and Uses Thereof	22-12-23	CI
OBI Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI

OBI Pharma, Inc. is a Taiwan-based company principally engaged in the development of new pharmaceuticals. The Company mainly operates its businesses through the research and development of novel cancer and infectious disease therapies. It also develops next generation active immunotherapies to treat cancers, including lung, prostate, pancreatic, stomach and ovarian cancers. It is engaged in the development of OBI-822 (formerly OPT-822/821), an active immunotherapy new drug for metastatic breast cancer; the research and development of therapeutic vaccine OBI-833 for the treatment of new generation of cancers, as well as the development of cancer testing reagent OBI-868.

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
OBI PHARMA, INC.	-11.38%	437M
MODERNA, INC.	+25.69%	47.86B
LONZA GROUP AG	+46.90%	41.42B
IQVIA HOLDINGS INC.	-3.46%	40.66B
CELLTRION, INC.	-6.20%	28.92B
ICON PUBLIC LIMITED COMPANY	+9.17%	25.55B
ALNYLAM PHARMACEUTICALS, INC.	-20.42%	19.27B
BIO-TECHNE CORPORATION	+0.17%	12.15B
MEDPACE HOLDINGS, INC.	+28.07%	12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.24%	11.99B